



NOVACYT EXTENDS USER BASE INTO MIDDLE EAST AND SECURES NEW PATENTS

- *Makes further progress in its new global expansion programme*
- *Early example of synergy created from the merger of Novacyt with Lab21*

Paris, France and Cambridge, UK – 8 September 2014 – Novacyt (ALTERNEXT: ALNOV), an international diagnostics manufacturer focused on cell-based diagnostics in the oncology and infectious disease markets, today announces the installation of the first fully automated NovaPrep® platform for cytology slide preparation in Kuwait as part of its international expansion plans.

The Kuwait installation will see a NPS25 platform system installed, along with a Novacyt Stainer, for use in gynecological liquid based cytology. This launch is the first example of the real commercial synergies that exist between the Novacyt and Lab21 distribution channels.

This launch is part of Novacyt's much wider and new commercialisation strategy developed following the recent merger with Lab21, a UK diagnostics company, in June 2014. Lab21 brought with it a strong global network of product sales and commercial channels and expertise in manufacturing and development. Having previously focused its sales in Europe, Novacyt is now active in developing new markets around the world and expects to report progress throughout the Middle East, Asia including China, Russia and USA in due course.

Novacyt has also been recently granted patents in China, the USA and Russia to further strengthen the company's strong IP position. The patents cover a number of innovations which improve future automatic screening of the NovaPrep® platform and separately cover innovations around scanning systems. These granted patents provide clear evidence of the target markets Novacyt intends to pursue whilst protecting the business as it increases its sales and marketing efforts in these markets.

Graham Mullis, CEO of Novacyt, said: "The installation of NovaPrep in Kuwait heralds the start of an expansion into the Middle East for Novacyt's cytology products, and we are aggressively expanding our commercial progress with our existing distributor channel across the region. In addition, the newly granted patents will strengthen our already excellent intellectual property position, and provide security as we roll out our global sales and marketing programme"

- Ends -

About Novacyt Group

The Novacyt Group is a leader in the field of diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NovaPrep®, and a strong international network provided by Lab21, its UK diagnostics subsidiary, it is able to provide an extensive range of oncology and infectious disease products globally. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com



Contacts:

For media and investor enquiries:

International Investor & Media

Tony Stephenson,

Exitus Communications,

+44 (0)7899 796655,

tony@exituscommunications.co.uk

French Investor & Media

Sophie Boulila / Emmanuel Huynh,

Newcap,

+33 (0)1 44 71 94 91,

novacyt@newcap.fr

NOVACYT

Graham Mullis

Chief Executive Officer

+44 7901 514121

Graham.mullis@novacyt.com